Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1333 to 1337 of 1337 entries
Sorted by: Best Match Show Resources per page
Comparison of clinically approved molecules on SARS-CoV-2 drug target proteins: a molecular docking study.

Turkish journal of chemistry

Çubuk H, Özbİl M.
PMID: 33679150
Turk J Chem. 2021 Feb 17;45(1):35-41. doi: 10.3906/kim-2008-35. eCollection 2021.

The new type of coronavirus, SARS-CoV-2 has affected more than 22.6 million people worldwide. Since the first day the virus was spotted in Wuhan, China, numerous drug design studies have been conducted all over the globe. Most of these...

Cite
Çubuk H, Özbİl M. Comparison of clinically approved molecules on SARS-CoV-2 drug target proteins: a molecular docking study. Turk J Chem. 2021;45(1):35-41doi: 10.3906/kim-2008-35.
Çubuk, H., & Özbİl, M. (2021). Comparison of clinically approved molecules on SARS-CoV-2 drug target proteins: a molecular docking study. Turkish journal of chemistry, 45(1), 35-41. https://doi.org/10.3906/kim-2008-35
Çubuk, Hasan, and Özbİl, Mehmet. "Comparison of clinically approved molecules on SARS-CoV-2 drug target proteins: a molecular docking study." Turkish journal of chemistry vol. 45,1 (2021): 35-41. doi: https://doi.org/10.3906/kim-2008-35
Çubuk H, Özbİl M. Comparison of clinically approved molecules on SARS-CoV-2 drug target proteins: a molecular docking study. Turk J Chem. 2021 Feb 17;45(1):35-41. doi: 10.3906/kim-2008-35. eCollection 2021. PMID: 33679150; PMCID: PMC7925319.
Copy Download .nbib Format: NLM
Recent advances in fungal serine protease inhibitors.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Burchacka E, Pięta P, Łupicka-Słowik A.
PMID: 34902742
Biomed Pharmacother. 2021 Dec 10;146:112523. doi: 10.1016/j.biopha.2021.112523. Epub 2021 Dec 10.

Four types of antifungal drugs are available that include inhibitors of ergosterol synthesis, of fungal RNA biosynthesis, and of cell wall biosynthesis as well as physiochemical regulators of fungal membrane sterols. Increasing resistance to antifungal drugs can severely limit...

Cite
Burchacka E, Pięta P, Łupicka-Słowik A. Recent advances in fungal serine protease inhibitors. Biomed Pharmacother. 2021;146:112523doi: 10.1016/j.biopha.2021.112523.
Burchacka, E., Pięta, P., & Łupicka-Słowik, A. (2021). Recent advances in fungal serine protease inhibitors. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 146112523. https://doi.org/10.1016/j.biopha.2021.112523
Burchacka, E, et al. "Recent advances in fungal serine protease inhibitors." Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie vol. 146 (2021): 112523. doi: https://doi.org/10.1016/j.biopha.2021.112523
Burchacka E, Pięta P, Łupicka-Słowik A. Recent advances in fungal serine protease inhibitors. Biomed Pharmacother. 2021 Dec 10;146:112523. doi: 10.1016/j.biopha.2021.112523. Epub 2021 Dec 10. PMID: 34902742.
Copy Download .nbib Format: NLM
Atypical response to bacterial coinfection and persistent neutrophilic bronchoalveolar inflammation distinguish critical COVID-19 from influenza.

JCI insight

Cambier S, Metzemaekers M, de Carvalho AC, Nooyens A, Jacobs C, Vanderbeke L, Malengier-Devlies B, Gouwy M, Heylen E, Meersseman P, Hermans G, Wauters E, Wilmer A, Schols D, Matthys P, Opdenakker G, Marques RE, Wauters J, Vandooren J, Proost P.
PMID: 34793331
JCI Insight. 2022 Jan 11;7(1). doi: 10.1172/jci.insight.155055.

Neutrophils are recognized as important circulating effector cells in the pathophysiology of severe coronavirus disease 2019 (COVID-19). However, their role within the inflamed lungs is incompletely understood. Here, we collected bronchoalveolar lavage (BAL) fluids and parallel blood samples of...

Cite
Cambier S, Metzemaekers M, de Carvalho AC, et al. Atypical response to bacterial coinfection and persistent neutrophilic bronchoalveolar inflammation distinguish critical COVID-19 from influenza. JCI Insight. 2022;7(1)doi: 10.1172/jci.insight.155055.
Cambier, S., Metzemaekers, M., de Carvalho, A. C., Nooyens, A., Jacobs, C., Vanderbeke, L., Malengier-Devlies, B., Gouwy, M., Heylen, E., Meersseman, P., Hermans, G., Wauters, E., Wilmer, A., Schols, D., Matthys, P., Opdenakker, G., Marques, R. E., Wauters, J., Vandooren, J., & Proost, P. (2022). Atypical response to bacterial coinfection and persistent neutrophilic bronchoalveolar inflammation distinguish critical COVID-19 from influenza. JCI insight, 7(1), . https://doi.org/10.1172/jci.insight.155055
Cambier, Seppe, et al. "Atypical response to bacterial coinfection and persistent neutrophilic bronchoalveolar inflammation distinguish critical COVID-19 from influenza." JCI insight vol. 7,1 (2022). doi: https://doi.org/10.1172/jci.insight.155055
Cambier S, Metzemaekers M, de Carvalho AC, Nooyens A, Jacobs C, Vanderbeke L, Malengier-Devlies B, Gouwy M, Heylen E, Meersseman P, Hermans G, Wauters E, Wilmer A, Schols D, Matthys P, Opdenakker G, Marques RE, Wauters J, Vandooren J, Proost P. Atypical response to bacterial coinfection and persistent neutrophilic bronchoalveolar inflammation distinguish critical COVID-19 from influenza. JCI Insight. 2022 Jan 11;7(1). doi: 10.1172/jci.insight.155055. PMID: 34793331.
Copy Download .nbib Format: NLM
Computational Simulation of HIV Protease Inhibitors to the Main Protease (Mpro) of SARS-CoV-2: Implications for COVID-19 Drugs Design.

Molecules (Basel, Switzerland)

Yu W, Wu X, Zhao Y, Chen C, Yang Z, Zhang X, Ren J, Wang Y, Wu C, Li C, Chen R, Wang X, Zheng W, Liao H, Yuan X.
PMID: 34885967
Molecules. 2021 Dec 05;26(23). doi: 10.3390/molecules26237385.

SARS-CoV-2 is highly homologous to SARS-CoV. To date, the main protease (Mpro) of SARS-CoV-2 is regarded as an important drug target for the treatment of Coronavirus Disease 2019 (COVID-19). Some experiments confirmed that several HIV protease inhibitors present the...

Cite
Yu W, Wu X, Zhao Y, et al. Computational Simulation of HIV Protease Inhibitors to the Main Protease (Mpro) of SARS-CoV-2: Implications for COVID-19 Drugs Design. Molecules. 2021;26(23)doi: 10.3390/molecules26237385.
Yu, W., Wu, X., Zhao, Y., Chen, C., Yang, Z., Zhang, X., Ren, J., Wang, Y., Wu, C., Li, C., Chen, R., Wang, X., Zheng, W., Liao, H., & Yuan, X. (2021). Computational Simulation of HIV Protease Inhibitors to the Main Protease (Mpro) of SARS-CoV-2: Implications for COVID-19 Drugs Design. Molecules (Basel, Switzerland), 26(23), . https://doi.org/10.3390/molecules26237385
Yu, Wei, et al. "Computational Simulation of HIV Protease Inhibitors to the Main Protease (Mpro) of SARS-CoV-2: Implications for COVID-19 Drugs Design." Molecules (Basel, Switzerland) vol. 26,23 (2021). doi: https://doi.org/10.3390/molecules26237385
Yu W, Wu X, Zhao Y, Chen C, Yang Z, Zhang X, Ren J, Wang Y, Wu C, Li C, Chen R, Wang X, Zheng W, Liao H, Yuan X. Computational Simulation of HIV Protease Inhibitors to the Main Protease (Mpro) of SARS-CoV-2: Implications for COVID-19 Drugs Design. Molecules. 2021 Dec 05;26(23). doi: 10.3390/molecules26237385. PMID: 34885967; PMCID: PMC8659229.
Copy Download .nbib Format: NLM
Profiles of liver fibrosis evolution during long-term tenofovir treatment in HIV-positive patients coinfected with hepatitis B.

Liver international : official journal of the International Association for the Study of the Liver

Dezanet LNC, Miailhes P, Lascoux-Combe C, Chas J, Maylin S, Gabassi A, Rougier H, Delaugerre C, Lacombe K, Boyd A.
PMID: 34297463
Liver Int. 2021 Jul 23; doi: 10.1111/liv.15019. Epub 2021 Jul 23.

BACKGROUND & AIMS: Data on liver fibrosis evolution and its involvement in liver-related morbidity are scarce in individuals with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) co-infection during treatment. We identified profiles of liver fibrosis evolution in...

Cite
Dezanet LNC, Miailhes P, Lascoux-Combe C, et al. Profiles of liver fibrosis evolution during long-term tenofovir treatment in HIV-positive patients coinfected with hepatitis B. Liver Int. 2021;doi: 10.1111/liv.15019.
Dezanet, L. N. C., Miailhes, P., Lascoux-Combe, C., Chas, J., Maylin, S., Gabassi, A., Rougier, H., Delaugerre, C., Lacombe, K., & Boyd, A. (2021). Profiles of liver fibrosis evolution during long-term tenofovir treatment in HIV-positive patients coinfected with hepatitis B. Liver international : official journal of the International Association for the Study of the Liver, . https://doi.org/10.1111/liv.15019
Dezanet, Lorenza N C, et al. "Profiles of liver fibrosis evolution during long-term tenofovir treatment in HIV-positive patients coinfected with hepatitis B." Liver international : official journal of the International Association for the Study of the Liver vol. (2021). doi: https://doi.org/10.1111/liv.15019
Dezanet LNC, Miailhes P, Lascoux-Combe C, Chas J, Maylin S, Gabassi A, Rougier H, Delaugerre C, Lacombe K, Boyd A. Profiles of liver fibrosis evolution during long-term tenofovir treatment in HIV-positive patients coinfected with hepatitis B. Liver Int. 2021 Jul 23; doi: 10.1111/liv.15019. Epub 2021 Jul 23. PMID: 34297463.
Copy Download .nbib Format: NLM
Showing 1333 to 1337 of 1337 entries